Securian Asset Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Securian Asset Management’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-78	Closed	-$32K	–	1000
2016 Q3	$32K	Hold	78	–	–	﹤0.01%	985
2016 Q2	$38K	Hold	78	–	–	﹤0.01%	987
2016 Q1	$40K	Hold	78	–	–	﹤0.01%	980
2015 Q4	$61K	Buy	+78	New	+$76.7K	﹤0.01%	989

Other funds holding HTGM

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIM

Sonora Investment Management Tucson, Arizona $798M AUM 17.61% 1-Year Est. Return

Ironwood Financial Tucson, Arizona $639M AUM 19.03% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Securian Asset Management's HTGM Position: Q4 2016 in Review

Securian Asset Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2016, closing a stake of 78 shares — an estimated $32K sold.

Securian Asset Management first reported a position in HTGM in Q4 2015 and held it in 4 quarters. The position peaked at $61K in Q4 2015. 13 funds tracked by Wall St. Rank hold HTGM as of Q4 2016.

Securian Asset Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
Securian Asset Management sold 78 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2016, an estimated $32K.
Securian Asset Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q4 2015 and held it in 4 quarters.
Securian Asset Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $61K in Q4 2015.
13 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2016.

Based on Securian Asset Management's 13F filing for Q4 2016, filed 10 Feb 2017.